Rotoplas Q2 2025 slides: Sequential improvement amid challenging year-over-year comps

Grupo Rotoplas (AGUA) reported mixed Q2 2025 results, showing sequential improvements with sales up 12% and EBITDA up 23% quarter-over-quarter, driven by strong U.S. market performance, despite year-over-year declines in both metrics. However, the company's financial leverage worsened significantly, with net financial debt to EBITDA rising to 3.2x from 1.8x a year ago, and it approved a reduced capital reimbursement of MXN 0.25 per share, indicating a cautious financial approach amid persistent market challenges.

Analysis

Grupo Rotoplas (AGUA) presented a mixed financial performance for Q2 2025, defined by a sequential operational recovery that has not yet offset significant year-over-year declines. While sales of 2,945 million MXN were down a marginal 0.9% from the prior year, they marked a 12% improvement from Q1 2025. Similarly, EBITDA of 369 million MXN fell 18% year-over-year but grew a robust 23% sequentially. This trend is further evidenced by the EBITDA margin, which at 13% is below the 15% from Q2 2024 but represents the third consecutive quarter of sequential expansion, suggesting a potential stabilization in profitability. The results highlight a sharp geographic divergence, with double-digit revenue growth and a positive EBITDA contribution from the U.S. market acting as a key bright spot against sales declines in the challenging Mexican market. However, the company's balance sheet has weakened considerably, as the net financial debt to EBITDA ratio deteriorated sharply to 3.2x from 1.8x a year earlier. This heightened leverage, combined with the board's decision to halve its capital reimbursement to MXN 0.25 per share, signals a deeply cautious management stance focused on capital preservation amid financial pressures.

Key Decisions for Investors

• Investors should weigh the encouraging sequential recovery in sales and EBITDA against the significant deterioration in the company's balance sheet, particularly the sharp increase in leverage to a 3.2x net debt-to-EBITDA ratio.
• The primary risk to monitor is the elevated leverage; any investment thesis should be contingent on the company demonstrating a clear path to reducing this ratio in subsequent quarters.
• Performance in the U.S. market is a critical catalyst, so investors should track this segment's contribution to revenue and profitability as a key indicator of the diversification strategy's success.
• The 50% reduction in the capital reimbursement, while negative for income-focused investors, is a prudent capital preservation move, and a future increase would serve as a strong positive signal of renewed financial stability.